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Abstract 
Background: Adjuvant chemotherapy in patients with resected esophageal squamous cell cancer (ESCC) remains 
controversial for its uncertain role in improving overall survival (OS). Nucleotide excision repair (NER) removes DNA-
adducts in tumor cells induced by the platinum-based chemotherapy and thus may modulate efficacy of the treat-
ment. The present study evaluated if single nucleotide polymorphisms (SNPs) of NER genes were prognostic biomark-
ers in ESCC patients treated with platinum-based adjuvant chemotherapy (PAC).
Methods: The analysis included 572 patients, for whom six SNPs of NER genes [i.e., XPC (rs1870134 and rs2228001), 
ERCC2/XPD rs238406 and ERCC5/XPG (rs2094258, rs2296147 and rs873601)] were detected with the TaqMan assay. 
Kaplan–Meier analyses and Cox proportional hazards models were used to evaluate their associations with disease 
free survival (DFS) and OS of these ESCC patients receiving PAC. Receiving operating characteristic curve analysis was 
used to evaluate the role of the risk genotypes in the DFS and OS.
Results: We found that ERCC5/XPG rs2094258 and rs873601 and ERCC2/XPD rs238406 SNPs were independently 
associated with poorer DFS and OS of ESCC patients [ERCC5/XPG rs2094258: CT+TT vs. CC: adjusted hazards ratio 
(adjHR) = 1.68 and P = 0.012 for DFS; adjHR = 1.99 and P = 0.0001 for OS; ERCC5/XPG rs873601: GA+GG vs. AA: 
adjHR = 1.59 and P = 0.024 for DFS; adjHR = 1.91 and P = 0.0005 for OS; ERCC2/XPD rs238406: TT vs. GG+GT: 
adjHR = 1.43 and P = 0.020 for DFS; adjHR = 1.52 and P = 0.008 for OS]. These HRs increased as the number of risk 
genotypes increased in the combined analysis. The model combining the risk genotypes with clinical characteristics 
or the TNM stage system was better in predicting outcomes in ESCC patients with PAC.
Conclusion: SNPs of ERCC2/XPD and ERCC5/XPG may independently and jointly predict survival of ESCC patients 
treated with PAC in this study population. Further validation in other study populations is warranted.
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Background
Esophageal cancer (EC), more than 90  % of which are 
esophageal squamous cell carcinoma (ESCC), is the 
fourth leading cause of cancer-related deaths in China 
[1]. To date, surgery remains the standard treatment for 
resectable ESCC in China. But, for those patients who 
received an esophagectomy alone, their 5-year survival is 
still in a disappointing range of 15–40  % [2]. As a con-
sequence, the surgery combined with adjuvant treatment 
has been employed to improve patients’ survival.
In recent years, neoadjuvant chemotherapy or neoad-
juvant chemoradiotherapy has been widely introduced 
as a standard regimen by various guides. Unfortunately, 
the results of some major multicenter prospective rand-
omized controlled trials (MPRCTs) were controversial. 
Besides, most of these trials were conducted in western 
countries, and more than 50  % of the patients included 
in these trials were diagnosed with an adenocarcinoma. 
Shapiro et al. [3] reported some overall survival (OS) ben-
efits when neoadjuvant chemoradiotherapy was added to 
surgery, while others all reported opposite conclusions 
[4–6]. Furthermore, the only one MPRCT conducted in 
Hong Kong Chinese patients with ESCC reported a nega-
tive conclusion [7]. Of the four MPRCTs employing neo-
adjuvant chemotherapy, two reported benefits in OS [8, 
9] but the other two did not [10, 11].
Adjuvant chemotherapy is not taken seriously in clini-
cal practice, because it is not thought as effective as it 
should be, and it may have impaired patients’ functions as 
a result of esophagectomy and prolonged convalescence 
that hamper patients’ timely administration of adjuvant 
therapy [12]. To date, only three MPRCTs about the effi-
cacy of platinum-based adjuvant chemotherapy (PAC) 
for EC have been published, among which two were 
conducted in Japanese ESCC patients. Although one did 
not yield the expected results [13], the other larger trial 
found an enhanced 5-year disease free survival (DFS) for 
patients with lymph node metastasis [14]. Traditionally, 
the anatomic and pathologic staging has been the most 
commonly used prognostic factors in EC patients, but 
it did not provide sufficient information for evaluating 
the efficacy of PAC, because it did not account for host 
factors, because genetic variants may interact with PAC 
and thus play a role in determining clinical response and 
prognosis of the patients.
In China, PAC is still the preference of many oncolo-
gists to treat EC patients [15]. Platinum compounds pro-
duce DNA adducts by reacting with DNA to form both 
intrastrand and interstrand cross-links in tumor cells, 
mainly with the N7 atom of guanine. These adducts result 
in a bulky distortion of the DNA helix, inhibit DNA rep-
lication, and eventually lead to cell death, if not repaired 
[16]. The amount of DNA adducts accumulated in tumor 
cells were correlated with the efficacy of platinum ther-
apy and had an impact on clinical outcome of the patients 
[17].
Nucleotide excision repair (NER), which participates 
in two path ways of DNA repair, global genomic repair 
and transcription-coupled repair, plays an important 
role in detection and repair of DNA damage caused 
by UV, tobacco-related carcinogens and other carci-
nogenic chemicals [18, 19], including DNA adducts 
formed by platinum [20]. Several xeroderma pigmen-
tosum (XP) group genes are involved in NER, includ-
ing group C (XPC), group D (ERCC2/XPD) and group 
G (ERCC5/XPG) [21–24]. Several studies suggested that 
single nucleotide polymorphisms (SNPs) in these three 
genes might be responsible for the variation in DNA 
repair capacity, leading to individual variation in cancer 
susceptibility and treatment response [25–28]. However, 
few reported studies have studied the SNPs’ roles in the 
prognosis of EC patients treated with PAC.
Therefore, we hypothesize that potentially functional 
SNPs of the three NER genes may modulate prognosis of 
EC patients treated with PAC. In this study, we selected 
six well-studied potentially functional SNPs of the NER 
genes, including three from ERCC5/XPG (rs2094258 
at 5′ near gene, rs22961475 at 5′ untranslated region 
(UTR) and rs873601 at 3′UTR), one from ERCC2/XPD 
(rs238406 at codon Arg156Arg) and two from XPC 
(rs1870134 at codon Val16Leu and rs2228001 at codon 
Lys939Gln) and evaluated their roles in survival of ethnic 
Han Chinese patients in eastern China.
Methods
Study population
The present study was done in a retrospective patient 
cohort in Fudan University Shanghai Cancer Center 
(Shanghai, China), and the research protocol was 
approved by the Institutional Ethics Review Board. Writ-
ten informed consents were obtained from all patients 
before blood samples were obtained for genotype test-
ing. Patients with perioperative mortality, defined as a 
death within 30 days of the operation or during the same 
hospitalization period, were excluded from the analysis. 
As a result, a cohort of 572 patients of ethnic Han Chi-
nese in eastern China, who received an esophagectomy 
and had pathologically confirmed ESCC in the Depart-
ment of Thoracic Surgery between March 2009 and 
December 2010, were included in the present study. Of 
these patients, additional 228 patients were excluded 
for the following reasons: 159 patients without under-
going postoperative chemotherapy for stage I disease, 
35 patients without complete follow-up information, 7 
patients for neoadjuvant chemotherapy and 27 patients 
for postoperative chemoradiotherapy. Therefore, the 
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final analysis included 344 patients who completed four 
cycles of adjuvant chemotherapy (Oxaliplatin 135  mg/
m2 d1 or cisplatin 40 mg/m2 d1–3 plus 5-Fu 750 mg/m2 
d1–5).
Demographic and clinical information of the patients 
was abstracted from the medical records. All patients 
were staged according to the 7th edition of the Ameri-
can Joint Committee on Cancer staging system. Survival 
data were obtained through the follow-up in outpatient 
clinics or by telephone calls quarterly upto Oct. 31, 2014. 
The DFS was defined as the time interval between the 
date of surgical resection and the first confirmed detec-
tion of local recurrence or the appearance of new metas-
tases. The OS duration of a patient was defined as the 
interval between surgical resection and the date of the 
latest follow-up or the death of the patients from any 
cause.
SNP selection and genotyping
We selected six potentially functional SNPs from the 
NCBI dbSNP database (http://www.ncbi.nlm.nih.
gov/) and the SNPinfo (http://snpinfo.niehs.nih.gov/). 
Genomic DNA was extracted from the buffy-coat frac-
tion of the blood samples using the Qiagen Blood DNA 
Mini Kit (Qiagen Inc., Valencia, CA). All the six SNPs 
were genotyped using the Taqman real-time PCR method 
with a 7900 HT sequence detector system (Applied Bio-
systems, Foster City, CA). The primers used in genotyp-
ing for these SNPs are listed in Additional file 1: Table S1. 
To ensure high genotyping accuracy, strict quality control 
procedures were implemented, and four duplicated posi-
tive controls and four negative controls (no DNA) were 
used in each of 384-well plates. Approximately 5 % of the 
samples were repeatedly genotyped, and the results were 
100 % concordant.
Statistical methods
Cox proportional hazards regression analysis was used to 
evaluate the effect of genotypes and clinicopathological 
variables on patients’ DFS and OS, calculated as hazards 
ratios (HRs) with their corresponding 95  % confidence 
intervals (CIs). Kaplan–Meier analysis was used to pre-
sent the visual effects of clinicopathological and genetic 
variables on the cumulative probability of DFS and OS. 
Receiver operating characteristic (ROC) analysis was 
used to compare sensitivity and specificity of predicting 
overall survival by the parameters. Statistical significance 
of the improvement in area under the receiver operator 
characteristic curve (AUC) after adding an explanatory 
factor was calculated by Delong’s test [29]. All reported 
P values were two-sided, and P < 0.05 was considered sta-
tistically significant. All analyses were performed using 
SAS software (version 9.2; SAS Institute, Cary, NC).
Results
Demographics and clinicopathological characteristics 
of ESCC patients and their associations with DFS and OS
The final analysis included 344 ESCC patients who 
received esophagectomy and PAC (Table  1) and had 
complete data on demographics, clinical characteristics, 
genotyping, DFS and OS. These patients aged between 
37 and 77  years at the time of diagnosis with a mean 
of 58.43  years and a standard deviation of 8.03  years. 
More patients were men than women (85.8 vs. 14.2  %), 
with 33.7  % of stage II and 66.3  % of stage III diseases, 
among whom 81.7 and 18.3 % underwent radical opera-
tion through two-field and  three-field lymphadenec-
tomy, respectively. The median follow-up time was 
36.13  months, during which 196 (57.0  %) patients died 
at the last follow-up. In multivariate analysis, three 
variables, i.e., TNM stage [adjusted hazards ratio 
(adjHR) = 1.55 and 95 % CI 1.13–2.12 for III vs. II], vessel 
invasion (adjHR = 1.44 and 95 % CI 1.07–1.94 for yes vs. 
no), and lymphadenectomy (adjHR =  1.42 and 95  % CI 
1.03–1.97 for three fields vs. two fields), were significantly 
associated with DFS (P < 0.05). The two variables, TNM 
stage (adjHR = 1.49 and 95 % CI 1.06–2.08 for III vs. II) 
and vessel invasion (adjHR = 1.56 and 95 % CI 1.14–2.12 
for yes vs. no) remained to be independent prognostic 
factors for OS (P < 0.05), but smoking (adjHR = 1.44 and 
95 % CI 1.01–2.07 for yes vs. no) instead of lymphadenec-
tomy became the third independent prognostic factor for 
OS.
Associations of selected SNPs with DFS and OS of ESCC 
patients
We assessed associations of six SNPs with DFS and OS of 
the 344 ESCC patients. In the multivariate analyses with 
adjustment for all the variables listed in Table 1, we found 
that DFS of the patients was significantly associated with 
ERCC5/XPG rs2094258 (CT+TT vs. CC: adjHR = 1.68, 
95 % CI 1.23–2.31, and P = 0.012), rs873601 (GG+GA vs. 
AA: adjHR = 1.59, 95 % CI 1.06–2.37, and P = 0.024), and 
ERCC2/XPD rs238406 (TT vs. GG+GT: adjHR =  1.43, 
95  % CI 1.06–1.93, and P  =  0.020) (Table  2). Similarly, 
we also found in the multivariate analyses that OS of the 
patients was significantly associated with ERCC5/XPG 
rs2094258 (CT+TT vs. CC: adjHR  =  1.99, 95  % CI 
1.40–2.81, and P = 0.0001), rs873601 (GG+GA vs. AA: 
adjHR = 1.91, 95 % CI 1.21–2.99, and P = 0.0005), and 
ERCC2/XPD rs238406 (TT vs. GG+GT: adjHR =  1.52, 
95 % CI 1.12–2.03, and P = 0.008) (Table 2).
To evaluate the collective effect of the significant SNPs 
on patients’ DFS and OS, we combined the risk geno-
types of ERCC5/XPG rs2094258CT/TT and rs873601 
GA/GG and ERCC2/XPD rs238406 TT for DFS and OS 
into a genotype score as the number of risk genotypes 
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(NRG). The frequencies of patients with a score of 0, 
1, 2 or 3 risk genotypes were 37, 63, 187 or 57, respec-
tively. For DFS, with the increasing NRG, patients had 
an increased risk of disease progression, compared 
with those carrying zero risk genotypes (Ptrend < 0.0001) 
(Table  2; Fig.  1a). Similarly, with the increasing NRG, 
risk of death increased correspondingly (Ptrend < 0.0001) 
(Table 2; Fig. 1c).
We then dichotomized all patients into a low-risk 
group (0–1 risk genotypes) (LG) and a high-risk group 
(2–3 risk genotypes) (HG) for further stratified analy-
sis. Compared with the LG, the HG had an obviously 
reduced DFS (adjHR  =  1.67, 95  % CI 1.20–2.34, and 
P = 0.003) (Table 2; Fig. 1b) and OS (adjHR = 1.77, 95 % 
CI 1.29–2.50, and P = 0.001) (Table 2; Fig. 1d).
Stratified analysis between the risk genotypes and survival 
of ESCC patients
We performed stratified analysis to assess whether the 
combined effect of risk genotypes (HG vs. LG) on DFS 
and OS was modified by some important demographic 
and clinicopathological factors listed in Table 1. For DFS 
or OS, we found that ESCC patients tended to exhibit 
an increased risk for disease progression or death in the 
subgroups with younger age (<60), of male, with smok-
ing and drinking history, with a relatively earlier stage, 
without vessel and neural invasion and with two-field 
lymphadenectomy (P  <  0.05) (Table  3 in multivari-
ate analysis and Additional file 2: Table S2 in univariate 
analysis).
ROC curve establish a new prognostic model 
with combined genotypes
Finally, we constructed a prognostic model combining 
all the independent prognostic factors: of risk genotypes, 
clinical characteristics (statistically significant factors in 
Table  1) and TNM stage for DFS and OS, and assessed 
the improvement of the model by adding risk genotypes 
to clinical characteristics and TNM stage by the ROC 
analysis. The combination of risk genotypes and clini-
cal characteristics (AUC: 0.704, 95  % CI 0.647–0.761, 
P  =  0.005 for DFS, AUC: 0.728, 95  % CI 0.674–0.782, 
P  =  0.004 for OS) showed a better prognostic value 
than did clinical characteristics (AUC: 0.649, 95  % CI 
0.591–0.707, P  =  0.005 for DFS; AUC: 0.662, 95  % CI 
0.605–0.720, P =  0.004 for OS) (Fig.  2a, c). Also, com-
bination of risk genotypes and TNM stage (AUC: 0.669, 
95  % CI 0.610–0.727, P  =  0.005 for DFS, AUC: 0.674, 
95 % CI 0.619–0.730, P < 0.0001 for OS) showed a better 
prognostic value than did TNM stage (AUC: 0.602, 95 % 
CI 0.549–0.655, P = 0.005 for DFS; AUC: 0.584, 95 % CI 
0.533–0.634, P < 0.0001 for OS) (Fig. 2b, d).
Fig. 1 Kaplan–Meier analysis for ESCC patients by combined risk genotypes. The combined risk genotypes were composed of ERCC5/XPG 
rs2094258CT/TT, rs873061GA/GG and ERCC2/XPG rs238406TT). a DFS by 0, 1, 2 and 3 NER variant genotypes (P = 0.0001). b DFS by 0–1 and 
2–3 NER variant genotypes (P = 0.0001). c OS by 0, 1 and 2 NER variant genotypes (P = 0.0001). d OS by 0–2 and 2–3 NER variant genotypes 
(P = 0.0002)
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Discussion
In this study, we reported that some SNPs of the NER 
genes, such as ERCC5/XPG rs2094258 and rs873601 
and ERCC2/XPD rs238406, may independently or 
jointly influence the prognosis of ESCC patients treated 
with PAC in eastern China. These genetic variants or 
genotypes, combined with some demographic and clin-
icopathological factors, once validated by others, may 
provide an improved prognostic tool for ESCC patients 
treated with PAC (Additional file 3: Table S3).
In the present study, we found that ERCC5/XPG 
rs2094258 CT/TT genotypes were associated with a 
decreased DFS and OS in ESCC patients treated with 
PAC. Although one previous study of 84 patients with 
squamous cell carcinomas did not find an association 
between the ERCC5/XPG rs2094258 SNP and response 
to PAC in non-small-cell lung cancer (NSCLC) [30], 
another study of 433 patients with advanced NSCLC did 
find an association between the ERCC5/XPG rs2094258 
SNP and outcome of PAC, with the conclusion consistent 
with the present study [31]. The rs2094258 SNP is located 
in the 5′ UTR of ERCC5/XPG, which is a putative tran-
scription factor binding site. Although genetic variants in 
gene promoters may alter gene expression levels and thus 
likely exert some influence on clinic outcome [25, 32, 33], 
there has been no report about biological or functional 
validation for this polymorphic site, which warrants addi-
tional mechanistic studies.
In the present study, we found that the ERCC2/XPD 
rs238406 TT genotype was associated with a reduced 
DFS and OS in ESCC patients, but few studies have 
reported its role in prognosis of cancer patients. One 
Taiwan study found that ERCC2/XPD rs238406 CC (or 
GG of its antisense) instead of the AA (or TT of its anti-
sense) genotype of 185 ESCC patients with neoadjuvant 
chemoirradiation followed by esophagectomy could 
additively increase risk of death and disease progres-
sion in cisplatin-based neoadjuvant concurrent chemo-
radiation therapy [34]. Contrary to their results, the TT 
genotype was associated with the worse DFS and OS in 
the present study. Another study showed that rs238406 
AA carriers had less efficiency of DNA adduct formation 
Table 3 Stratified multivariate analysis of DFS and OS between LG* and HG* in Chinese ESCC patients
* LG consisted of 0–1 risk genotypes and HG consisted of 2–3 risk genotypes













 <60 149/32 86 (57.7)/24 (75.0) 1.94 (1.21–3.10) 0.006 71 (47.7)/24 (75.0) 2.41 (1.49–3.90) 0.0004
 ≥60 138/25 89 (64.5)/21 (84.0) 1.40 (0.85–2.32) 0.187 81 (58.7)/20 (80.0) 1.27 (0.76–2.14) 0.360
Sex
 Male 246/49 153 (62.2)/41(83.7) 1.76 (1.24–2.51) 0.002 133 (54.1)/40 (81.6) 1.89 (1.32–2.71) 0.0005
 Female 41/8 22 (53.7)/4 (50) 0.62 (0.16–2.32) 0.474 19 (46.3)/4 (50.0) 074 (0.19–2.90) 0.660
Smoking
 Never 100/22 56 (56.0)/16 (72.7) 1.54 (0.86–1.74) 0.146 45 (45.0)/16 (72.7) 1.74 (0.96–3.17) 0.069
 Yes 187/35 119 (63.6)/29 (82.9) 1.71 (1.12–2.60) 0.012 107 (57.2)/28 (80.0) 1.77 (1.16–2.72) 0.008
Drinking
 No 143/28 82 (57.3)/21 (75) 1.74 (1.05–2.87) 0.032 72 (50.4)/20 (71.4) 1.87 (1.11–3.15) 0.018
 Yes 144/29 93 (64.6)/24 (82.8) 1.74 (1.08–2.80) 0.022 80 (55.6)/24 (82.8) 1.93 (1.20–3.12) 0.007
Vessel invasion
 No 207/36 114 (55.1)/28 (77.8) 2.38 (1.56–3.63) <0.001 96 (46.4)/26 (72.2) 2.07 (1.33–3.22) 0.001
 Yes 80/21 61 (76.3)/17 (81.0) 1.12 (0.64–2.95) 0.699 56 (70.0)/28 (85.7) 1.61 (0.92–2.83) 0.098
Neural invasion
 No 214/40 129 (60.3)/32 (80.0) 1.72 (1.16–2.55) 0.007 111 (51.9)/30 (75.0) 1.71 (1.13–1.58) 0.011
 Yes 73/17 46 (63.0)/13 (76.5) 1.29 (0.64–2.59) 0.477 41 (56.2)/14 (82.4) 1.54 (0.75–3.16) 0.241
TNM stage
 II 96/20 43 (44.8)/15 (75.0) 2.06 (1.14–3.72) 0.006 38 (39.6)/14 (70) 2.40 (1.29–4.45) 0.006
 III 191/37 132 (69.1)/30 (81.1) 1.44 (0.95–2.17) 0.084 114 (59.7)/30 (81.1) 1.62 (1.07–2.45) 0.024
Lymphadenectomy
 Two fields 237/44 138 (58.2)/34 (77.3) 1.67 (1.13–2.45) 0.009 119 (50.2)/34 (77.3) 1.99 (1.34–1.94) 0.006
 Three fields 50/13 37 (74.0)/11 (84.6) 2.17 (1.00–4.74) 0.051 33 (66.0)/10 (76.9) 1.59 (0.72–3.52) 0.256
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in their lymphocytes [35], suggesting that cells with the 
rs238406 AA genotype may have a highly-efficient capa-
bility to remove DNA adducts, leading to a relatively 
quicker recovery from the genotoxic effects of PAC and 
thus drug resistance with shortened DFS and OS. On 
the other hand, the rs238406 AA genotype may lead to 
patients’ relatively mild therapeutic toxicity. For exam-
ple, one study demonstrated that patients with the 
rs238406 AA genotype, who received oxaliplatin-based 
chemotherapy, suffered less grade 3 toxicities [36]. The 
Fig. 2 ROC analyses in ESCC patients. P values show the area under the ROC curves (AUC) of the three different models. Clinical characteristic 
include the statistically significant variables in multivariate analysis in Table 1. a ROC analyses of the prediction of DFS by the risk genotypes model, 
the clinical characteristics model, and the combined risk genotypes and clinical characteristics model. b ROC analyses of the prediction of DFS by 
the risk genotypes model, the TNM stage model, and the combined risk genotypes and TNM stage model. Clinical characteristic include the statisti-
cally significant variables in multivariate analysis in Table 1. c ROC analyses of the prediction of OS by the risk genotypes model, the clinical charac-
teristics model, and the combined risk genotypes and clinical characteristics model. d ROC analyses of the prediction of OS by the risk genotypes 
model, the TNM stage model, and the combined risk genotypes and TNM stage model
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discrepancy between Lee’s [34] and our findings per-
haps may lie in the following aspects: the present study 
included only patients with squamous carcinomas, while 
Lee’s included additional patients with adenocarcinomas; 
patients received chemotherapy in the present study but 
concurrent chemo-radiation therapy in Lee’s study; and 
all the patients were ethnic Han Chinese in the present 
study but various ethnic groups of patients in Taiwan in 
Lee’s study.
We also found that patients with the ERCC5/XPG 
rs873601 GA/GG genotypes had an increased risk of pro-
gression and death of ESCC after PAC, which was not 
reported before. One study reported that the rs873601 G 
allele was associated with better PFS and OS of patients 
with advanced NSCLC, which may be disease-specific 
and need to be validated in future studies [37].
It is likely that the effect of a single SNP on clinical out-
come may be much restricted, but the combined effect 
of several SNPs in the same or different genes could be 
much greater. Indeed, we found that the collective effect 
of the risk genotypes identified in the present study bet-
ter predicted DFS and OS of the patients. Compared with 
some clinical factors, genetic variants such as SNPs may 
have a weaker effect on prognosis. As shown by ROC 
curves in the present study, SNPs had almost the same 
effect on prognosis as the TNM stage, although it served 
a relatively inferior role in prognosis, compared with 
other clinical characteristics that included clinical char-
acteristics such as smoking, vessel invasion, neural inva-
sion, TNM stage and lymphadenectomy.
In the stratified analyses, we found that the genotype-
survival association was more evident for a mild status of 
clinical characteristics, such as without vessel and neural 
invasion, II stage, two-field lymphadenectomy, which is 
consistent with what were reported in Lee’s study for EC 
with neoadjuvant chemoradiation and esophagectomy 
[34]. It is likely that the severe effects of a later TNM 
stage and vessel invasion as poor prognosis factors [38–
40] on the survival may have masked those benefit form 
genetic factors.
There were some limitations in the present study. First, 
patients included in the analyses were from one hospital 
in eastern China, which may not represent the general 
population. Second, only six putatively functional SNPs 
of three NER genes were tested in the study, and there 
were other genetic variants in these genes or other NER 
pathway genes that may affect the prognosis of ESCC. 
Finally, the present study was retrospective instead of a 
prospective or randomized design, thus the bias caused 
by other possible factors, such as standardization of dose 
and the judgment of disease progress, could not have 
been completely excluded.
Conclusions
In summary, we identified that ERCC5/XPG rs2094258 
CT/TT and rs873601 GA/GG and ERCC2/XPD rs238406 
TT genotypes may independently or jointly affect sur-
vival of ESCC patients treated with PAC. These findings, 
once validated in future prospective studies with large 
sample sizes and better study designs, will provide some 
promising guidance for personalized treatment for ESCC 
patients in the adjuvant setting in China.
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